Related Experiment Video
Updated: May 3, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Gabapentinoids confer survival benefit in human glioblastoma
Joshua D Bernstock1,2,3, Mulki Mehari4, Jakob V E Gerstl5,6
1Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. jbernstock@bwh.harvard.edu.
Abstract:
Neuronal-glioma interactions are increasingly recognized as critical in the development and progression of central nervous system tumors. Recent research highlights that gliomas can integrate into neural circuits through various mechanisms, including the synaptogenic factor thrombospondin-1 (TSP-1). This new mechanistic understanding of cancer neuroscience allows for novel insights into target discovery. Critically, therapies that modulate neuron-tumor interactions remain agnostic to other oncogenic changes within tumor cells yet may still target fundamental drivers of tumor growth. In line with these findings and controlling for critical confounding variables, we demonstrate a survival benefit associated with gabapentin (an antagonist of TSP-1) following surgical resection of newly diagnosed glioblastoma. This retrospective, multi-institutional cohort study included 1,072 patients, with a discovery cohort of 693 patients and an additional 379 patients from a separate site for external validation. Furthermore, our findings indicate that gabapentin administration is associated with reduced serum TSP-1 levels, suggesting its potential as a future biomarker.
Insights
Gabapentin, an antagonist of thrombospondin-1 (TSP-1), improved survival in glioblastoma patients after surgery. This suggests targeting neuron-tumor interactions offers a novel therapeutic strategy for brain tumors.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Neuronal-glioma interactions are crucial in central nervous system tumor development.
- Gliomas can integrate into neural circuits via factors like thrombospondin-1 (TSP-1).
- Targeting these interactions offers a novel therapeutic approach, independent of tumor cell genetics.
Purpose of the Study:
- To investigate the survival benefit of gabapentin, a TSP-1 antagonist, in glioblastoma patients post-surgery.
- To explore the potential of gabapentin as a therapeutic agent by modulating neuron-tumor interactions.
- To assess TSP-1 levels as a potential biomarker in response to gabapentin.
Main Methods:
- Retrospective, multi-institutional cohort study.
- Inclusion of 1,072 patients (693 in discovery cohort, 379 in validation cohort).
- Analysis of survival data and serum TSP-1 levels in glioblastoma patients.
Main Results:
- Gabapentin administration was associated with a significant survival benefit after surgical resection of newly diagnosed glioblastoma.
- Gabapentin treatment correlated with reduced serum TSP-1 levels.
- The findings were validated across independent patient cohorts.
Conclusions:
- Modulating neuron-tumor interactions with gabapentin represents a promising therapeutic strategy for glioblastoma.
- Gabapentin may offer a survival advantage in glioblastoma patients.
- Serum TSP-1 levels could serve as a predictive biomarker for gabapentin efficacy.
Related Concept Videos
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...